Rockwell Medical, Inc. (RMTI) on Focus After Raising In Today’s Session

Rockwell Medical, Inc. (NASDAQ:RMTI) Logo

Investors sentiment increased to 3.64 in Q2 2019. Its up 2.52, from 1.12 in 2019Q1. It is positive, as 3 investors sold Rockwell Medical, Inc. shares while 11 reduced holdings. 21 funds opened positions while 30 raised stakes. 31.25 million shares or 184.99% more from 10.96 million shares in 2019Q1 were reported.
343,910 are owned by D E Shaw. 3.66 million were reported by Blackrock Inc. Johnson Investment Counsel invested in 0% or 27,650 shares. Vanguard Incorporated has 2.85M shares. 40,750 are owned by Balasa Dinverno And Foltz Ltd Co. Tower Rech Ltd Liability Corp (Trc) accumulated 4,245 shares. Signaturefd Ltd Liability holds 0% or 500 shares in its portfolio. Manatuck Hill Lc has invested 0.18% in Rockwell Medical, Inc. (NASDAQ:RMTI). Grp One Trading L P holds 12,668 shares. Rhumbline Advisers has invested 0% in Rockwell Medical, Inc. (NASDAQ:RMTI). Voya Investment Mngmt Lc has 25,297 shares. Perkins Capital Mgmt holds 952,800 shares. 31,200 are owned by Bridgeway Cap Mngmt. Morgan Stanley holds 177,019 shares. Raymond James Assoc stated it has 0% of its portfolio in Rockwell Medical, Inc. (NASDAQ:RMTI).

Since March 15, 2019, it had 8 insider purchases, and 0 sales for $1.09 million activity. $9,048 worth of Rockwell Medical, Inc. (NASDAQ:RMTI) was bought by Richmond David S.. 10,000 Rockwell Medical, Inc. (NASDAQ:RMTI) shares with value of $29,700 were bought by Paul Stuart M.

The stock of Rockwell Medical, Inc. (NASDAQ:RMTI) is a huge mover today! The stock increased 4.12% or $0.12 during the last trading session, reaching $3.03. About 186,609 shares traded. Rockwell Medical, Inc. (NASDAQ:RMTI) has declined 34.48% since September 13, 2018 and is downtrending. It has underperformed by 34.48% the S&P500.
The move comes after 7 months positive chart setup for the $193.39 million company. It was reported on Sep, 13 by Barchart.com. We have $3.12 PT which if reached, will make NASDAQ:RMTI worth $5.80 million more.

Analysts await Rockwell Medical, Inc. (NASDAQ:RMTI) to report earnings on November, 8. They expect $-0.14 EPS, down 40.00 % or $0.04 from last year’s $-0.1 per share. After $-0.18 actual EPS reported by Rockwell Medical, Inc. for the previous quarter, Wall Street now forecasts -22.22 % EPS growth.

Rockwell Medical, Inc. (NASDAQ:RMTI) Ratings Coverage

Among 3 analysts covering Rockwell Med (NASDAQ:RMTI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rockwell Med has $12 highest and $10 lowest target. $11’s average target is 263.04% above currents $3.03 stock price. Rockwell Med had 6 analyst reports since March 18, 2019 according to SRatingsIntel. H.C. Wainwright maintained Rockwell Medical, Inc. (NASDAQ:RMTI) on Tuesday, June 25 with “Buy” rating. On Monday, June 24 the stock rating was initiated by Cantor Fitzgerald with “Buy”. Piper Jaffray initiated Rockwell Medical, Inc. (NASDAQ:RMTI) rating on Monday, June 24. Piper Jaffray has “Buy” rating and $10 target.

More notable recent Rockwell Medical, Inc. (NASDAQ:RMTI) news were published by: Nasdaq.com which released: “Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 08, 2019, also Crainsdetroit.com with their article: “New Rockwell Medical CEO talks about turnaround after controversy – Crain’s Detroit Business” published on May 19, 2019, Globenewswire.com published: “Rockwell Medical, Inc. to Discuss First Quarter 2019 Financial Results on May 9, 2019 – GlobeNewswire” on May 02, 2019. More interesting news about Rockwell Medical, Inc. (NASDAQ:RMTI) were released by: Seekingalpha.com and their article: “Possible Turnaround At Rockwell Medical – Seeking Alpha” published on September 05, 2019 as well as Seekingalpha.com‘s news article titled: “FDA accepts Rockwell’s application for IV Triferic; shares up 9% premarket – Seeking Alpha” with publication date: August 06, 2019.

Rockwell Medical, Inc. operates as an integrated biopharmaceutical firm in the United States and internationally. The company has market cap of $193.39 million. It offers services and products for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. It currently has negative earnings. The companyÂ’s lead drug is Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment via dialysate.

Rockwell Medical, Inc. (NASDAQ:RMTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.